Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The rats suffering from MI had decreased survival rates and exhibited reduced levels of NO, high-density lipoprotein cholesterol, and lumen diameter, and Smad7 messenger RNA (mRNA) and protein expression; while had significantly increased ratio of heart weight or body weight, levels of ET-1, inflammatory factors, blood lipid indexes, vascular remodeling indexes, collagen volume fraction, vulnerable atherosclerotic plaque area, VCAM-1 and MMP-2 protein expression, TGF-β, Smad2, Smad3, and Smad4 mRNA and protein expression.
|
30317569 |
2019 |
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
EDN1-primed MSCs were superior to naive MSCs at 8 weeks after MI in improving myocardial contractility (p < 0.05), reducing fibrosis area (p < 0.05), increasing engraftment efficiency (p < 0.05), and improving capillary density (p < 0.05).
|
31194009 |
2019 |
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, compared with the MI group, the plasma levels of TXA2, ET-1 and vWF contents signififi cantly decreased in the MI+SSYX group, and the ET-1 mRNA expression levels of myocardium in the border zone significantly decreased, and the VEGF, PGI2 and eNOS mRNA expression levels signififi cantly increased (all P<0.05).
|
30656600 |
2019 |
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Biomechanical stress in myocardial infarctions: can endothelin-1 and growth differentiation factor 15 serve as immunohistochemical markers?
|
29151120 |
2018 |
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
The actions of ET-1 are evident during normal adaptive physiological responses and increased under pathophysiological conditions, such as following myocardial infarction and during heart failure, where ET-1 levels are elevated.
|
29470978 |
2018 |
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
Concentrations of ET-1 above the median were associated with shorter time to incident HF, MI, cardiovascular mortality, all-cause mortality, and the composite of incident HF/MI/cardiovascular mortality (all log-rank <i>P</i> < 0.001).
|
30213784 |
2018 |
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Lack of association between endothelin-1 gene variants and myocardial infarction.
|
19672034 |
2009 |
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Patients with ischemic heart disease (IHD) and previous MI showed a difference in the distribution of genotype G8002A for endothelin-1: allele G 0.718 and A 0.282 vs those without MI: allele G 0.882 and A 0.118, (p<0.05).
|
18442814 |
2008 |
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
C-terminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study.
|
17893002 |
2007 |
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
The endothelin system and its role in acute myocardial infarction.
|
15161426 |
2004 |
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
LHGDN |
Pathophysiology of endothelin and medical emergencies.
|
12855940 |
2003 |
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to examine whether molecular variations at the endothelin-1 locus were involved in susceptibility to myocardial infarction and variation in blood pressure.
|
10334806 |
1999 |
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
RGD |
Myocardial expression of endothelin-2 is altered reciprocally to that of endothelin-1 during ischemia of cardiomyocytes in vitro and during heart failure in vivo.
|
10573185 |
1999 |